drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR T-cell therapy)
drug_description
Autologous mRNA-engineered BCMA-directed CAR T-cell therapy in which patient T cells are transiently modified to express a chimeric antigen receptor targeting B-cell maturation antigen (BCMA), resulting in CAR-mediated T-cell activation and cytotoxicity against myeloma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous patient T cells are transiently mRNA-engineered to express a BCMA-targeted chimeric antigen receptor; CAR binding to BCMA on myeloma cells activates the T cells to release cytotoxic effectors and kill BCMA-positive plasma cells, with transient expression limiting persistence and avoiding genomic integration.
drug_name
Descartes-15
nct_id_drug_ref
NCT06304636